Unión Europea - rumano - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, tulpina cvd 103-hgr, live - holeră - vaccinuri - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. acest vaccin ar trebui să fie utilizate în conformitate cu recomandările oficiale.

Unión Europea - rumano - EMA (European Medicines Agency)

tetris pharma b.v - glucagon - diabetul zaharat - pancreatic hormoni, hormoni glycogenolytic - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Unión Europea - rumano - EMA (European Medicines Agency)

advicenne s.a. - potassium citrate monohydrated, potassium hydrogen carbonate - acidosis, renal tubular - mineral supplements - sibnayal is indicated for the treatment of distal renal tubular acidosis (drta) in adults, adolescents and children aged one year and older.

Unión Europea - rumano - EMA (European Medicines Agency)

rhythm pharmaceuticals netherlands b.v. - setmelanotide - obezitatea - preparate antiobezitate, excl. produse alimentare - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Unión Europea - rumano - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - blocaj blocant - toate celelalte produse terapeutice - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Unión Europea - rumano - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - blocaj blocant - toate celelalte produse terapeutice - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Unión Europea - rumano - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - blocaj blocant - toate celelalte produse terapeutice - inversarea blocadei neuromusculare indusă de rocuroniu sau vecuroniu. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Unión Europea - rumano - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolactona - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 și 5.

Unión Europea - rumano - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - blocaj blocant - toate celelalte produse terapeutice - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Unión Europea - rumano - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - insuficienta cardiaca - antagoniști ai angiotensinei ii, alte combinații, agenți care acționează asupra sistemului renină-angiotensină - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.